Q3 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript
Greetings, and thank you for standing by, and welcome to the Navidea Biopharmaceuticals Q3 2020 Earnings and Business Call. (Operator Instructions) This conference is being recorded, Thursday, November 12, 2020.
And now I'd like to turn the conference over to Jed Latkin, CEO, COO and CFO. Please go ahead.
Thank you, Scott. This call is -- first off, I just want to start with us saying that this call is being webcast live on our website, ir.navidea.com, and a replay will be made available. Following the prepared remarks here, we're just going to do a Q&A as well, as always.
During the course of the conference call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Navidea's molecular diagnostics and immunotherapeutics, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |